ESC
VRTX icon

Eurizon SLJ Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Eurizon SLJ Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.54M Sell
21,523
-2,633
-11% -$1.23M 4.54% 7
2025
Q4 		$11M Buy
+24,156
New +$10.4M 4.34% 6

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Eurizon SLJ Capital's VRTX Position: Q1 2026 in Review

Eurizon SLJ Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, selling an estimated $1.23M and leaving 21,523 shares worth $9.54M. The position accounts for 4.54% of the portfolio, ranked #7.

Eurizon SLJ Capital first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $11M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Eurizon SLJ Capital held 21,523 shares of Vertex Pharmaceuticals worth $9.54M as of Q1 2026.
  • Eurizon SLJ Capital sold 2,633 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.23M.
  • Vertex Pharmaceuticals made up 4.54% of Eurizon SLJ Capital's portfolio in Q1 2026, its #7 holding.
  • Eurizon SLJ Capital first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Eurizon SLJ Capital's Vertex Pharmaceuticals position peaked at $11M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Eurizon SLJ Capital's 13F filing for Q1 2026, filed 6 May 2026.